Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice.

Endocrinology

Cardiovascular Biochemistry Laboratory (E.P., A.M., B.A.D., D.Y., M.J., J.G.), Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada H2X 0A9; Department of Medicine (E.P., J.-L.C., M.J., J.G.), Québec, Canada H3T 1J4; and Department of Physiology (T.L.B.), Midwestern University, Glendale, Arizona 85308.

Published: April 2015

Oxytocin (OT) is involved in the regulation of energy metabolism and in the activation of cardioprotective mechanisms. We evaluated whether chronic treatment with OT could prevent the metabolic and cardiac abnormalities associated with diabetes and obesity using the db/db mice model. Four-week-old male db/db mice and their lean nondiabetic littermates (db/+) serving as controls were treated with OT (125 ng/kg · h) or saline vehicle for a period of 12 weeks. Compared with db/+ mice, the saline-treated db/db mice developed obesity, hyperglycemia, and hyperinsulinemia. These mice also exhibited a deficient cardiac OT/natriuretic system and developed systolic and diastolic dysfunction resulting from cardiomyocyte hypertrophy, fibrosis, and apoptosis. These abnormalities were associated with increased reactive oxygen species (ROS) production, inflammation, and suppressed 5'-adenosine monophosphate kinase signaling pathway. The db/db mice displayed reduced serum levels of adiponectin and adipsin and elevated resistin. OT treatment increased circulating OT levels, significantly reduced serum resistin, body fat accumulation (19%; P<.001), fasting blood glucose levels by (23%; P<.001), and improved glucose tolerance and insulin sensitivity. OT also normalized cardiac OT receptors, atrial natriuretic peptide, and brain natriuretic peptide, expressions and prevented systolic and diastolic dysfunction as well as cardiomyocyte hypertrophy, fibrosis, and apoptosis. Furthermore, OT reduced cardiac oxidative stress and inflammation and normalized the 5'-adenosine monophosphate-activated protein kinase signaling pathway. The complete normalization of cardiac structure and function by OT treatment in db/db mice contrasted with only partial improvement of hyperglycemia and hyperinsulinemia. These results indicate that chronic treatment with OT partially improves glucose and fat metabolism and reverses abnormal cardiac structural remodeling, preventing cardiac dysfunction in db/db mice.

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2014-1718DOI Listing

Publication Analysis

Top Keywords

db/db mice
20
male db/db
8
abnormalities associated
8
reduced serum
8
mice
7
db/db
5
oxytocin treatment
4
treatment prevents
4
prevents cardiomyopathy
4
cardiomyopathy observed
4

Similar Publications

Purpose: The retina contains the highest concentration of the omega 3 fatty acid, docosahexaenoic acid (DHA), in the body. Although epidemiologic studies showed an inverse correlation between the consumption of omega 3 fatty acids and the prevalence of diabetic retinopathy, there are no data showing the effect of diabetes on retinal DHA in humans. In this study, we measured the DHA content of the retina in diabetic and non-diabetic humans as well as mice and determined the effect of diabetes on retinal thickness and function in mice.

View Article and Find Full Text PDF

Mass Spectrometry Imaging Reveals Spatial Metabolic Alterations and Salidroside's Effects in Diabetic Encephalopathy.

Metabolites

December 2024

Key Laboratory of Mass Spectrometry Imaging and Metabolomics, Minzu University of China, National Ethnic Affairs Commission, Beijing 100081, China.

Diabetic encephalopathy (DE) is a neurological complication of diabetes marked by cognitive decline and complex metabolic disturbances. Salidroside (SAL), a natural compound with antioxidant and neuroprotective properties, has shown promise in alleviating diabetic complications. Exploring the spatial metabolic reprogramming in DE and elucidating SAL's metabolic effects are critical for deepening our understanding of its pathogenesis and developing effective therapeutic strategies.

View Article and Find Full Text PDF

Background: Diabetes often causes diabetic nephropathy (DN), a serious long-term complication. It is characterized by chronic proteinuria, hypertension, and kidney function decline, can progress to end-stage renal disease, lowering patients' quality of life and lifespan. Inflammation and apoptosis are key to DN development.

View Article and Find Full Text PDF
Article Synopsis
  • Diabetic kidney disease (DKD) is a major cause of kidney failure, largely due to damage in podocytes, which are essential for kidney function.
  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key player in protecting cells from oxidative stress, making it a promising target for DKD therapies.
  • The study found that DDO-1039, a new Nrf2 activator, improved kidney health in diabetic mice by reducing podocyte injury, lowering blood sugar levels, and decreasing inflammation, endorsing its potential as a treatment for DKD.
View Article and Find Full Text PDF

Low expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse model.

Biochem Biophys Res Commun

December 2024

Yancheng Clinical College, Xuzhou Medical University, Yancheng, 224000, PR China. Electronic address:

Diabetes is one of the most prevalent metabolic disorders, and its incidence has been experiencing a steady annual rise in recent years. Diabetic peripheral neuropathy (DPN) represents the most frequent adverse complication, exerting a profound impact on the quality of life for those suffering from diabetes. The etiology of DPN is complex, including impaired mitochondrial function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!